NovaBridge Biosciences filed a Form 6-K on October 28, 2026, announcing the appointment of Charles "Chuck" Silberstein, M.D., M.B.A., CFA as Chief Financial Officer, effective November 2, 2026, following the resignation of Ming (Kyler) Lei.

Key Highlights

  • New CFO appointed: Charles "Chuck" Silberstein, M.D., M.B.A., CFA will assume the role of Chief Financial Officer effective November 2, 2026.
  • Outgoing CFO: Ming (Kyler) Lei tendered his resignation as Chief Financial Officer, effective October 30, 2026.
  • No disagreement cited: According to the filing, Lei's resignation "was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices."
  • Prior role: Dr. Silberstein served as Co-Founder and Chief Executive Officer of FytonBio, Inc. from May 2024 to October 2026 and will continue as a member of its board of directors.
  • Earlier CFO experience: Dr. Silberstein previously served as CFO of GentiBio, Inc. from February 2022 to May 2024, and as CFO and Head of Business Development of Applied Therapeutics from May 2020 to January 2022.
  • Education: Dr. Silberstein holds an M.D. from Albert Einstein College of Medicine, an M.B.A. in Finance from Columbia Business School, and a B.A. in Biology from Yeshiva University.

CFO Transition at NovaBridge Biosciences: Silberstein Succeeds Lei

According to the filing, NovaBridge Biosciences announced on October 28, 2026 that Dr. Charles Silberstein will become its Chief Financial Officer on November 2, 2026. He succeeds Ming (Kyler) Lei, whose resignation takes effect October 30, 2026. The company disclosed that Lei's departure did not stem from any disagreement over operations, policies, or practices, and it expressed appreciation for his service during his tenure.

The filing details Dr. Silberstein's career history across finance, pharmaceutical, and bioscience roles. Before his time as Co-Founder and CEO of FytonBio, Inc. (May 2024 to October 2026), he held CFO positions at GentiBio, Inc. and Applied Therapeutics. Prior to that, from 2018 to May 2020, he served as Senior Vice President of Corporate Business Development and R&D Strategy at Allergan plc. His earlier career included roles at J.P. Morgan Asset Management (Executive Director and Senior Healthcare Analyst, 2015 to 2018), The Boston Company Asset Management, LLC (Director, Portfolio Manager and Senior Healthcare Analyst, 2006 to 2014), and Goldman Sachs Asset Management (Portfolio Manager, Vice President and Healthcare Analyst, 2000 to 2005).

The Form 6-K was signed by Srishti Gupta, Chief Executive Officer of NovaBridge Biosciences, and was furnished under Commission File Number 001-39173. The filing notes that its contents, excluding Exhibit 99.1, are incorporated by reference into the company's registration statements on Form F-3 (File No. 333-286954) and Form S-8, among others. A press release announcing Dr. Silberstein's appointment was attached as Exhibit 99.1.

What Was Disclosed

NovaBridge Biosciences reported a CFO transition: Ming (Kyler) Lei resigned effective October 30, 2026, and Charles Silberstein, M.D., M.B.A., CFA was appointed CFO effective November 2, 2026, with no disagreement cited as the cause of Lei's departure.